FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to oncology, and can be used to predict the effectiveness of neoadjuvant chemoradiation therapy (NDCT) in patients with rectal cancer during primary MRI examination. Texture analysis of the MRI image of the primary tumor in T2-WI mode is performed. For analysis, MRI images obtained in the axial plane at the level of the center of the tumor using an FSE pulse sequence with high spatial resolution are used: TR (sequence repetition period) - 4020 ms, TE (echo appearance time) - 97 ms, slice thickness/step - 3.0/0.3 mm, FoV (field of view size) - 250 mm, MTX (matrix size/pixels) - 286×512. Next, the selected images are loaded into the Mazda ver.4.6 program and the image segmentation is carried out. The texture parameters are determined by the GLCM gray level co-occurrence matrix method at a distance of 2 pixels and in four different directions - 0°, 45°, 90°, 135°. The obtained values are averaged and, using a computer program, the parameters of texture analysis are automatically calculated, which are used to predict the effectiveness of NHLT based on the scoring system. AngScMom - if it is greater than or equal to 0.0016, then 1 point is assigned, if less than 0.0016 - 0 points. SumofSqs - if less than or equal to 101.88, then 1 point is assigned, if more than 101.88 - 0 points. SumVarnc - if less than or equal to 277.51, then 1 point is assigned, if more than 277.51 - 0 points. SumEntrp - if less than or equal to 1.81, then 1 point is assigned, if more than 1.81 - 0 points. Entropy - if less than or equal to 2.88, then 1 point is assigned, if more than 2.88 - 0 points. If the sum of the received points is greater than or equal to 3, then a good response to NDCT is predicted. If the sum of the received points is less than 3, then no response to NDCT is predicted.
EFFECT: invention provides prediction of the effectiveness of NDCT due to quantitative data of 5 parameters of texture analysis (AngScMom, SumVarnc, SumofSqs, Entropy, SumEntrp) T2-WI magnetic resonance imaging of the tumor during the primary MRI study.
1 cl, 11 dwg, 4 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR ASSESSING THE EFFECTIVENESS OF THE NEOADJUVANT CHEMORADIOTHERAPY IN PATIENTS SUFFERING RECTAL CANCER | 2019 |
|
RU2705257C2 |
METHOD OF TREATING PATIENTS WITH METASTASES IN LYMPH NODES AND OLIGOMETASTATIC DISEASE IN BONES OF SKELETON IN PROSTATE CANCER | 2018 |
|
RU2695348C2 |
METHOD FOR COMBINED TREATMENT OF PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER USING NEOADJUVANT RADIATION THERAPY AND CONSOLIDATING CHEMOTHERAPY | 2021 |
|
RU2770989C2 |
METHOD FOR PREDICTION OF PROBABILITY OF DEGREE OF MALIGNANCY OF ACINAR PROSTATE ADENOCARCINOMA IN MALES BY GLEASON SCALE 7=3+4 AND 7=4+3 ON BASIS OF BPMRT-RADIOMICS | 2023 |
|
RU2825524C1 |
METHOD OF COMBINED TREATMENT OF MUSCULO-INVASIVE BLADDER CANCER T3-T4 N0-+M0 | 2019 |
|
RU2713443C2 |
METHOD FOR PREOPERATIVE DETERMINATION OF MORPHOLOGICAL RISK FACTORS FOR PROGRESSION IN PATIENTS WITH PROSTATE CANCER | 2021 |
|
RU2770983C1 |
METHOD OF TREATMENT OF LOCALLY ADVANCED SQUAMOUS CELL CANCER OF ANAL CANAL | 2023 |
|
RU2809447C2 |
PROGNOSIS METHOD FOR DISEASE PROGRESSION IN PATIENTS WITH GASTROINTESTINAL CANCER AFTER TREATMENT | 2021 |
|
RU2758079C2 |
METHOD OF NEOADJUVANT THERMOCHEMORADIATION TREATMENT OF RECTAL CANCER | 2018 |
|
RU2704205C2 |
METHOD FOR ULTRASONIC EXAMINATION OF PATIENTS DIAGNOSED WITH ENDOMETRIAL CANCER | 2020 |
|
RU2739108C2 |
Authors
Dates
2021-09-02—Published
2021-03-17—Filed